Troy Luster, PhD
Executive Director, Cell Engineering
Over the past 15 years, Troy led research-based target discovery and validation efforts focused primarily on oncology targets. He was previously at Intellia Therapeutics building complex in vitro and in vivo functional genetic screening platforms to discover “immune enhancing edits” for incorporation into CRISPR modified cell therapy products. Prior to Intellia, he worked at the Belfer Center within the Dana-Farber Cancer Institute, collaborating with DFCI investigators and industry partners to discover new epigenetic targets. Troy began his biotech career in the Washington DC area, spending 5 years at Human Genomic Sciences (acquired by GSK in 2012), researching antibody-based therapeutics for cancer. His training includes a post-doc at UT Southwestern Medical Center, a PhD from the University of Nebraska Medical Center, and a BS from the University of Nebraska-Lincoln.